1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their ...
1. Participants identifying as South Asian or Black were more likely to test positive for COVID-19 infection, be hospitalized for ...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. ...
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one ...
1. The AstraZeneca vaccine was 70.4% effective against the B.1.1.7 lineage, compared to 81.5% effective against non-B.1.1.7 lineages. 2. The ...
1. Overall vaccine efficacy at least 14-days after the second dose was 66.7%. 2. After the initial 21-day exclusion period, ...
1. Efficacy of the Gam-COVID-Vac (Sputnik V) vaccine against COVID-19 was 91.6%. 2. In the vaccine group, there were no ...
1. Novel SARS-CoV-2 vaccine SCB-2019 was well-tolerated amongst both younger and older adults. 2. SCB-2019 adjuvanted with AS03 or CpG/Alum ...
1. The ChAdOx1 nCoV-19 vaccine against COVID-19 was well-tolerated overall, with reduced reactogenicity in older adults. 2. The ChAdOx1 nCoV-19 ...
